Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RECALLS & COURT ACTIONS: Oct. 28 & Nov. 4, 1992

Executive Summary

CLASS III -- ACNE DAY LOTION An OTC drug packaged in 2 ounce and 16 ounce containers, a non-PABA sunscreen. Recall number: D-050-3. Lot number 2786. Manufacturer: Chemolee Labs, Inc., Irving, Texas. Recalled by: Manufacturer, by telephone Aug. 1, 1992. Firm-initiated recall ongoing. Distribution: California; Firm estimates none remains on the market. Reason: Presence of mold. CLASS III -- PAT DUER DIURETIC TABLETS An herbal product, in plastic bottles of 90 and 250 tablets. Recall number: D-049-3. Code 103792 EXP 12/93. Manufacturer: Fibertone/Patten, also known as Naturally Vitamin supplements, Scottsdale, Arizona. Recalled by: Manufacturer, by letter Aug. 14, 1992. Firm-initiated recall ongoing. Distribution: California, Illinois, Oregon, Texas, Utah, Washington state; 37 bottles of 90 tablets each and 37 bottles of 250 tablets each were distributed. Reason: Current good manufacturing practice deficiencies. SEIZURES -- CALCIUM PANGAMATE TABLETS (92-607-526). Charge: Adulterated -- The product contains the food additive, N, N-dimethylglycine, which is unsafe because there is no regulation in effect prescribing the conditions under which the additive may be safely used. Firm: General Nutrition Corporation, Inc., Leetsdale, Pennsylvania. Filed: June 5, 1992 -- U.S. District Court for the Western District of Pennsylvania; Civil number 92-1388; FDC number 66377. Seized: June 29, 1992 -- goods valued at approximately $3,775. SEIZURES -- NOLATRIM-75 PHENYLPROPANOLAMINE HYDROCHLORIDE TIMED RELEASE CAPSULES (92-630-655). Charge: Adulterated -- The methods used in, and the facilities and controls used for, the product's manufacture, processing, and holding do not conform to and are not operated and administered in conformity with current good manufacturing practice regulations. Misbranded -- The product's label fails to contain the correct place of business of the distributor. Firm: Wesley Pharmacal Company, Ivyland, Pennsylvania. Filed: Sept. 22, 1992; U.S. District Court for the Eastern District of Pennsylvania; Civil number 92CV5491; FDC number 66601. Seized: Sept. 28, 1992 -- 93 bottles, valued at approximately $2,697.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel